Orsini Specialty Pharmacy

Overview

Orsini Specialty Pharmacy is a rare disease and cell / gene therapy specialty pharmacy that pairs dispensing with patient-services hub, home-infusion, third-party logistics, and manufacturer data capabilities under one operating roof. Recent public launch materials show Orsini acting as exclusive specialty pharmacy, hub services partner, home-infusion partner, and 3PL commercialization partner depending on the product; the integrated model is the differentiator versus dispense-only peers.

Orsini should not be evaluated as a high-volume oncology generalist, a PBM-owned specialty pharmacy, or a stand-alone hub. It is an independent rare-disease and CGT operator backed by Carlyle Group and Consonance Capital Partners. Best-fit launches are rare disease or complex therapy programs where patient counts are small, payer documentation is heavy, handling requirements are specialized, and the manufacturer wants fewer handoffs across hub, pharmacy, nursing, logistics, and data vendors. Compare Orsini directly with PANTHERx Rare, Biologics by McKesson, Accredo / Evernorth, CVS Specialty, OptumRx Specialty, and Eversana when deciding between an independent rare disease specialist, a PBM-owned generalist, a wholesaler-owned model, or a broader commercialization-services platform.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Orsini Specialty Pharmacy is evaluated as rare disease and cell / gene therapy specialty pharmacy that pairs dispensing with patient-services hub, home-infusion, third-party logistics, and manufacturer data capabilities under one operating roof.

Capability	Buyer should compare	Orsini Specialty Pharmacy readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. Orsini’s Columbus facility is publicly described as fully operational and licensed to dispense medication in all 50 states, adding redundancy to the Elk Grove Village operating base. Accreditation signal. Orsini displays rare-disease and specialty-pharmacy accreditation signals; buyers should confirm product-specific REMS, audit, and clinical-trial dispensing responsibilities.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Major coverage workflow. The LOARGYS launch names Orsini as exclusive specialty pharmacy and hub services partner, with support for medication access, insurance coverage, and financial assistance.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Major engagement model. Public materials describe therapy care teams, clinical management, and patient-services support across rare disease and gene therapy programs.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Major logistics workflow. The Columbus facility adds co-located 3PL capabilities and advanced ultra-cold storage for gene and cell therapy programs.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Important diligence point. Orsini markets ORBIT technology, ORBIT Track, and real-world data capabilities; buyers should review product-specific reporting templates and data-feed timing before award.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Differentiated where product fit requires it. The AVLAYAH launch names Orsini as exclusive specialty pharmacy and home-infusion partner.

Buyer Fit

• Primary buying context: Include Orsini for rare disease, ultra-rare, gene therapy, enzyme-replacement, or complex specialty launches where the manufacturer wants an integrated SP + hub + infusion + logistics partner instead of stitching four vendors together.
• Profile signal: Independent rare-disease and CGT specialty pharmacy with 50-state Columbus dispensing licensure, ultra-cold storage, co-located 3PL, ORBIT data tooling, and a documented track record of exclusive and single-source launch roles.
• Best-fit therapies: Products with exclusive or single-source distribution models, small patient populations, heavy insurance documentation, home infusion needs, ultra-cold storage, or high need for coordinated patient support.
• Less ideal fit: High-volume specialty programs that prioritize PBM-owned routing power, oncology launches that need oncology-specialist scale, or oral specialty products that do not benefit from infusion / 3PL adjacency.
• Commercial fit: Pricing is undisclosed; assume RFP-led scope with launch-role choice (exclusive SP, single-source SP, hub partner, home-infusion partner, 3PL), data feeds, and staffing model defined in the SOW.
• SOW diligence: Product-specific payer access, hub handoff rules, data cadence, patient-services staffing, 3PL service levels, ultra-cold requirements, home-infusion scope, and how Orsini coordinates with any separate manufacturer hub or field access team.

Differentiators

• Integrated operating model: Orsini can credibly pitch a combined specialty pharmacy, hub, home infusion, and 3PL model rather than a dispensing-only role.
• Rare disease specialization: Public company materials position Orsini around rare disease and gene therapy patients, with therapy care teams and rare disease accreditations.
• Launch-role breadth: Recent public announcements cover exclusive specialty pharmacy, single-source specialty pharmacy, hub services, home infusion, and 3PL.
• Columbus redundancy and cold-chain infrastructure: The Columbus facility adds national dispensing licensure, co-located logistics, and ultra-cold storage for gene and cell therapy programs.
• ORBIT data layer: Orsini’s current public taxonomy includes ORBIT technology, real-world data, manufacturer visibility, and customizable workflow rules as part of the biopharma service offer.
• Accreditation signal: Orsini publicly cites ACHC, The Joint Commission, URAC, and NABP accreditations, plus URAC Rare Disease Pharmacy Center of Excellence and ACHC Distinction in Rare Diseases and Orphan Drugs.

RFP Questions

• Which states, payer networks, prescriber channels, and LDD pathways can Orsini access for this exact product?
• What parts of benefits investigation, prior authorization, appeals, copay, PAP, and foundation support will Orsini handle versus a separate hub?
• What is the therapy-specific staffing model across pharmacist, nurse, reimbursement specialist, care coordinator, and escalation roles?
• Which home-infusion, nursing, site-of-care, REMS, ultra-cold, and 3PL requirements are internal capabilities versus partner-dependent workflows?
• What reports will the manufacturer receive for time-to-fill, abandonment, refill persistence, unresolved barriers, inventory, and patient status, and how often?
• How will ORBIT, ORBIT Track, or other manufacturer-facing data tools integrate with the hub CRM, data warehouse, field access team, and medical affairs reporting?
• Which quick-start, private-label, clinical-trial dispensing, direct-to-home, or direct-to-site workflows are in scope for this product?
• How does Orsini create continuity between specialty pharmacy, hub, home infusion, and 3PL workflows when it is not the only vendor in the launch model?

Recent Activity

• April 2026: Selected by Denali Therapeutics as exclusive specialty pharmacy and home-infusion partner for AVLAYAH in pediatric Hunter syndrome / MPS II.
• March 2026: Named single-source specialty pharmacy partner for Glaukos’ Epioxa for keratoconus.
• March 2026: Selected by Immedica Pharma US as exclusive specialty pharmacy and hub services partner for LOARGYS, with 3PL support also tied to the program.
• January 2026: Selected as a specialty pharmacy partner for Cytokinetics’ MYQORZO for obstructive hypertrophic cardiomyopathy.
• October 2025: Launched an integrated specialty pharmacy and 3PL solution supported by the Columbus, Ohio facility.
• April 2025: Launched ORBIT Track, a manufacturer-collaboration portal for case visibility, messaging, territory access, and patient-progress reporting.